

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
PO BOX 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

ADD ICA TON			Alexandria, Virginia 22313-1450 www.uspto.gov		
APPLICATION NO	D. FILING DATE	FIRST NAMED INVENTOR			
09/903,325	07/11/2001		ATTORNEY DOCKET NO.	CONFIRMATION NO.	
33401		Edward M. De Robertis	510015-257	8377	
	7590 07/24/2003			·	
MCDERMOTT, WILL & EMERY (LOS ANGELES OFFICE) EXAMINED					
34TH FLOOR			EXAMINER		
LOS ANGI	LOS ANGELES, CA 90067-3208			ROMEO, DAVID S	
			ART UNIT	PAPER NUMBER	
			1647		
			DATE MAILED: 07/24/2003	9	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
	0.00	09/903,325				
	Office Action Summary	L	DE ROBERTIS ET AL.			
		Examiner	Art Unit			
Pe	The MAILING DATE of this communication a riod for Reply	David S Romeo	1647			
		appears on the cover sheet w	with the correspondence address			
	THE MAILING DATE OF THIS COMMUNICATION Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a ref. NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mail	PLY IS SET TO EXPIRE 1 N. R. 1.136(a). In no event, however, may a preply within the statutory minimum of thir	MONTH(S) FROM reply be timely filed			
			· · · · · · · · · · · · · · · · · · ·			
	This action is Furnishment attorn(s) filed on 11					
	This action is FINAL. 2h) T	This action is				
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is Disposition of Claims 10 Since this application is in condition for allowance except for formal matters, prosecution as to the merits is Disposition of Claims					
	Claim(s) 6-8,11 and 12 is/are pending in the a		7. 11, 100 0.G. 213.			
	4a) Of the above claim(a)	application.				
5)	4a) Of the above claim(s) is/are withdra) Claim(s) is/are allowed.	wn from consideration.				
6)) Claim(s) is/are rejected.					
7)'	Claim(s)					
, , , , , , ,	is/are objected to					
Applic	☑ Claim(s) <u>6-8,11 and 12</u> are subject to restriction cation Papers	n and/or election requireme	L			
9)[The energies	· ·-·· · · · · · · · · · · · · · · · ·	rit.			
10)[The specification is objected to by the Examiner	г.				
,-	The drawing(s) filed on is/are: a)☐ accept Applicant may not request that any objection to the	oted or b) objected to by the	Francisco			
11)	Applicant may not request that any objection to the The proposed drawing correction filed on	drawing(s) be held in abeyance	Examiner.			
,_	The proposed drawing correction filed on If approved, corrected drawings are required in reply	is: a)☐ approved b)☐ disa	e. See 37 CFR 1.85(a).			
121	If approved, corrected drawings are required in reply	v to this Office action	pproved by the Examiner.			
Dai a mide	of acciding is objected to by the Ever	miner.	1			
·	7 dilder 35 U.S.C. §§ 119 and 120					
13)[_]	Acknowledgment is made of a claim for foreign a		1			
a'	Acknowledgment is made of a claim for foreign p □ All b)□ Some * c)□ None of:	priority under 35 U.S.C. § 11	19(a)-(d) or (f).			
	Certified copies of the priority documents h Certified copies of the priority documents h Certified copies of the priority documents h		1			
	2. Certified copies of the priority documents h	nave been received.				
	2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in Application No. application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office agriculture for the priority documents have been received in this National Stage					
* 5	application from the International Burea See the attached detailed Office agrees for a live	/ documents have been rece au (PCT Rule 17.2(a)).	eived in this National Stage			
(a)	The translation of the factor	priority under 35 U.S.C. § 119	9(e) (to a provisional application)			
Attachment(Acknowledgment is made of a claim for domestic provisi (s)	rionty under 35 U.S.C. §§ 17	20 and/or 121			
1) L Notice	e of References Citad (BTO and		12.			
3) Informa	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	i i i i i i i i i i i i i i i i i i i	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)			
U.S. Patent and Trad PTO-326 (Rev.	/. 04-01)	, _				
	Office Action S	Summary	Part of Paper No. 09			
			ration raper No. 09			

Application/Control Number: 09/903,325 Art Unit: 1647

5

20

Page 2

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 6-8, 12 drawn to a FRZB-1 polypeptide, classified in class 530, subclass 350.
- Claim 11, to the extent that it is drawn to a polynucleotide comprising the II. nucleotide sequence of SEQ ID NO: 4, classified in class 536, subclass 23.5. III.
- Claim 11, to the extent that it is drawn to a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 8, classified in class 536, subclass 23.5.
- 10 Claim 11, to the extent that it is drawn to a polynucleotide comprising the IV. nucleotide sequence of SEQ ID NO: 10, classified in class 536, subclass 23.5.

The inventions are distinct, each from the other because of the following reasons:

The polynucleotides of Inventions II-IV are related to the polypeptide of Invention I by virtue of encoding same. The polynucleotide has utility for the recombinant production of the polypeptide in a host cell. Although the polynucleotide and polypeptide are related since the 15 polynucleotide encodes the specifically claimed polypeptide, they are distinct inventions because they are physically and functionally distinct chemical entities, and the polypeptide product can be made by another and materially different process, such as by synthetic polypeptide synthesis or purification form the natural source. Further, the polynucleotide may be used for processes other than the production of the polypeptide, such as a nucleic acid hybridization assay.

The following pairwise combinations of products are independent and distinct, wherein neither member of a pair is required for the production or use of the other, and wherein each of

Application/Control Number: 09/903,325

Art Unit: 1647

5

10

15

20

Page 3

the pair can be manufactured independently of the other and used for independent and distinct purposes: II and each of III-IV; III and IV. Further, nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the searches required are not coextensive, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Claim 12 is generic to a plurality of disclosed patentably distinct species comprising:

- 1. a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 4 or comprising the amino acid sequence of SEQ ID NO: 3;
- 2. a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 8 or comprising the amino acid sequence of SEQ ID NO: 7; and

Application/Control Number: 09/903,325

Art Unit: 1647

Page 4

3. a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 10 or comprising the amino acid sequence of SEQ ID NO: 9.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

10

5

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

15

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

20

25

ANY INQUIRY CONCERNING THIS COMMUNICATION OR EARLIER COMMUNICATIONS FROM THE EXAMINER SHOULD BE DIRECTED TO DAVID S. ROMEO WHOSE TELEPHONE NUMBER IS (703) 305-4050. THE EXAMINER CAN NORMALLY BE REACHED ON MONDAY THROUGH

IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, GARY KUNZ, CAN BE REACHED ON (703) 308-4623.

Application/Control Number: 09/903,325 Art Unit: 1647 Page 5 . IF SUBMITTING OFFICIAL CORRESPONDENCE BY FAX, APPLICANTS ARE ENCOURAGED TO SUBMIT OFFICIAL CORRESPONDENCE TO THE FOLLOWING TC 1600 BEFORE AND AFTER FINAL RIGHTFAX NUMBERS: BEFORE FINAL (703) 872-9306 AFTER FINAL (703) 872-9307 5 IN ADDITION TO THE OFFICIAL RIGHTFAX NUMBERS ABOVE, THE TC 1600 FAX CENTER HAS THE FOLLOWING OFFICIAL FAX NUMBERS: (703) 305-3592, (703) 308-4242 AND (703) 305-3014. CUSTOMERS ARE ALSO ADVISED TO USE CERTIFICATE OF FACSIMILE PROCEDURES WHEN SUBMITTING A REPLY TO A NON-FINAL OR FINAL OFFICE ACTION BY FACSIMILE (SEE 37 CFR 1.6 AND 1.8). FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (703) 308-0294. 10 ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.

15

DAVID ROMEO PRIMARY EXAMINER ART UNIT 1647

20 DSR JULY 22, 2003